Satapathy, Sanjaya K.

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,035

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 497

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 260

Community socioeconomic deprivation predicts nonalcoholic steatohepatitis

Giammarino, A. M., Qiu, H., Bulsara, K., Khan, S., Jiang, Y., Da, B. L., Bernstein, D. E., & Satapathy, S. K. (2022) · Hepatology Communications

Liver Disease Diagnosis and TreatmentHealth disparities and outcomes

Cited by 47

Decreasing frequency and improved outcomes of hepatitis C‐related liver transplantation in the era of direct‐acting antivirals – a retrospective cohort study

Arora, S. S., Axley, P., Ahmed, Z., Satapathy, S. K., Wong, R., Kuo, Y., & Singal, A. K. (2019) · Transplant International

Hepatitis C virus researchOrgan Transplantation Techniques and Outcomes

Cited by 24